Deepening Jiangxi–Hong Kong Exchanges to Jointly Promote Market Prosperity: A Delegation from the Hong Kong Special Administrative Region Government’s Economic and Trade Office in Wuhan Visits Our Company for Inspection and Exchange

Published:

2026-11-02


On the morning of October 29, 2026, as the autumn breeze brought refreshing coolness, a long-awaited rendezvous between Jiangxi and Hong Kong unfolded as scheduled. Director Cai Minjun of the Hong Kong Special Administrative Region Government’s Economic and Trade Office in Wuhan, accompanied by a delegation of nine members, paid a visit to Jiangxi Biological Products Research Institute Co., Ltd. (hereinafter referred to as “Jiangxi Bio” or the “Company,” stock code: 6915.HK). With relevant leaders from the Ji’an Municipal Government Office in attendance, the delegation gained an in-depth understanding of the company’s internationalization strategy leveraging Hong Kong’s capital markets, while jointly exploring new avenues for high-quality mainland biopharmaceutical enterprises to contribute to the prosperity of the Hong Kong market. The Company’s Deputy General Manager, Hu Xiande, provided full‑time accompaniment throughout the visit.

During the visit, the delegation toured the company’s production facilities and observed the entire product‑manufacturing process on site. Deputy General Manager Hu Xiande provided a detailed briefing, covering the company’s evolution, its integrated industrial‑chain strategy, the development of its R&D team, its pipeline of innovative products under development, and its long-term growth plans. As a leading domestic anti‑serum enterprise listed on the Main Board of the Hong Kong Stock Exchange in June 2026, Jiangxi Bio adheres to the mission of “providing high‑quality medicines to people worldwide.” With more than five decades of dedicated expertise in the biopharmaceutical sector, the company maintains rigorous quality control, exporting its products to over 30 countries participating in the Belt and Road Initiative. By 2025, its sales are expected to account for nearly 100% of China’s exports of comparable products and 45.8% of the global market, bolstering both the Hong Kong capital markets and the broader biopharmaceutical industry with solid operational performance.

During the visit, Director Cai Minjun highly commended Jiangxi Bio’s achievements in establishing a strong foothold in the Jinggangshan Economic Development Zone, steadfastly pursuing independent innovation, deeply cultivating the emergency‑care biologics sector, and leveraging its Hong Kong platform to expand into international markets. She noted that, as a mainland biopharmaceutical company listed on the Main Board of the Hong Kong Stock Exchange, Jiangxi Bio has injected fresh vitality and robust momentum into the diversification of Hong Kong’s capital market and the growth of the biopharmaceutical industry through equity financing, international regulatory registration, and global market expansion. With its unique strengths in international investment and financing, trade channels, pharmaceutical regulatory approval, and intellectual property, the Hong Kong Economic and Trade Office in Wuhan will continue to serve as a vital bridge for economic and trade cooperation between Jiangxi and Hong Kong, supporting more high‑quality mainland enterprises in listing in Hong Kong and tapping into its business opportunities, thereby working together to foster the prosperity and development of the Hong Kong market.

Both sides unanimously agreed to take this on-site visit and exchange as an opportunity to maintain ongoing communication and coordination, explore new avenues for cooperation in areas such as biopharmaceutical R&D, international market development, and talent exchange, and leverage Hong Kong’s international advantages to facilitate the mutual flow of resources and the complementary strengths of Jiangxi and Hong Kong in the biopharmaceutical sector. Together, they will work to foster a thriving biopharmaceutical market in Hong Kong and promote the high-quality, coordinated development of the broader health industry.

Mountains and seas are no barrier to distance; Jiangxi and Hong Kong are one family. This fact-finding mission and exchange vividly demonstrated the proactive efforts of mainland biopharmaceutical companies in leveraging Hong Kong’s platform to support the development of the Hong Kong market, forging strong ties that facilitate the company’s access to Hong Kong’s international resources. Moving forward, the company will remain committed to innovation-driven growth, refine its core products, accelerate the commercialization of new offerings, and continue to deepen its presence in both the Hong Kong capital market and the global marketplace. By delivering even higher‑quality biologics, we aim to safeguard patients in China and around the world, while further advancing exchanges and collaboration between Jiangxi and Hong Kong in the biopharmaceutical sector.

Contact us

Add:

Address: No. 198 Huoju Avenue, Jinggangshan Economic & Technological Development Zone, Ji’an, Jiangxi, China

Board Office:

Domestic Sales:

International Sales:

Complaint & Report Hotline:

Pharmacovigilance Hotline:

Company Email:

Investor Relations:

International Sales Email:

Complaint/Report Email:

二维码

WeChat mini-site

二维码

WeChat official account


© Copyright 2025 Jiangxi Institute of Biological Products Inc. | SEO

Business License

Powered by www.300.cn